Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
3
Regulatory Approvals
No patent data available. Pre-approval drugs may not have Orange Book listings.
Vijoice
Treatment of patients with severe manifestations of PIK3CA-related overgrowth spectrum
Vijoice
Treatment of adult and paediatric patients aged 2 years and older with severe or life-threatening manifestations of PIK3CA-related overgrowth spectrum (PROS)
Piqray
Piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy (see section 5.1).
View on EMAMultiple Sclerosis
Solid Tumors
Chronic Obstructive Pulmonary Disease
Influenza
Swine-Origin Influenza A H1N1 Virus